首页 > 最新文献

Journal of Pharmaceutical Health Care and Sciences最新文献

英文 中文
Impact of pharmacist-led aminoglycoside stewardship: a 10-year observational study.
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-28 DOI: 10.1186/s40780-024-00399-x
Yasutaka Shinoda, Kengo Ohashi, Tomoko Matsuoka, Kaori Arai, Nao Hotta, Eiseki Usami

Background: Aminoglycosides are crucial for treating multidrug-resistant gram-negative infections and endocarditis. However, aminoglycosides are associated with significant risks of nephrotoxicity, necessitating careful dose selection and therapeutic drug monitoring. Therapeutic drug monitoring is essential for minimizing risk; however, few institutions routinely perform it. This study aimed to assess the impact of a pharmacist-driven therapeutic drug monitoring intervention on aminoglycoside usage trends and clinical outcomes.

Methods: This retrospective cohort study included 263 patients treated with aminoglycosides between 2014 and 2023. A pharmacist-led therapeutic drug monitoring intervention began in 2017, focusing on monitoring renal function, documenting patient weight, and closely managing aminoglycoside concentrations. Trends in aminoglycoside use and renal outcomes were analyzed.

Results: Over the study period, appropriate use of aminoglycosides at the time of initial prescription increased from 49 to 82% (P < 0.01). Pharmacist dosing design at initial prescription increased significantly from 21% pre-intervention to 60% post-intervention (P < 0.01). The proportion of pharmacist intervention in initial dosing design increased over time. The proportion of patients with measured aminoglycoside blood concentrations significantly increased from 53% pre-intervention to 72% post-intervention (P < 0.01). The proportion of patients who were able to manage target blood concentrations from the initial aminoglycoside dose without dose adjustments increased from 31% pre-intervention to 42% post-intervention, although the results were not significantly different (P = 0.07). The incidence rate of renal impairment remained similar (11% vs. 12%; P = 0.85), although the annual average number of cases decreased from 4.3 before the intervention to 2.5 after. Similarly, there were no significant differences in clinical efficacy before and after the intervention (65% vs. 71%; P = 0.35). Furthermore, aminoglycoside stewardship led to a 56% cost saving.

Conclusions: Pharmacist-led aminoglycoside stewardship significantly improved the appropriate use of aminoglycosides and decreased the associated costs. Thus, pharmacist involvement is essential for the proper use of aminoglycosides. However, many patients required aminoglycoside dose reductions despite the pharmacist's guideline-based dosing design. Therefore, further accumulation of information on the management of aminoglycoside blood concentration may be necessary for the revision of these guidelines.

{"title":"Impact of pharmacist-led aminoglycoside stewardship: a 10-year observational study.","authors":"Yasutaka Shinoda, Kengo Ohashi, Tomoko Matsuoka, Kaori Arai, Nao Hotta, Eiseki Usami","doi":"10.1186/s40780-024-00399-x","DOIUrl":"10.1186/s40780-024-00399-x","url":null,"abstract":"<p><strong>Background: </strong>Aminoglycosides are crucial for treating multidrug-resistant gram-negative infections and endocarditis. However, aminoglycosides are associated with significant risks of nephrotoxicity, necessitating careful dose selection and therapeutic drug monitoring. Therapeutic drug monitoring is essential for minimizing risk; however, few institutions routinely perform it. This study aimed to assess the impact of a pharmacist-driven therapeutic drug monitoring intervention on aminoglycoside usage trends and clinical outcomes.</p><p><strong>Methods: </strong>This retrospective cohort study included 263 patients treated with aminoglycosides between 2014 and 2023. A pharmacist-led therapeutic drug monitoring intervention began in 2017, focusing on monitoring renal function, documenting patient weight, and closely managing aminoglycoside concentrations. Trends in aminoglycoside use and renal outcomes were analyzed.</p><p><strong>Results: </strong>Over the study period, appropriate use of aminoglycosides at the time of initial prescription increased from 49 to 82% (P < 0.01). Pharmacist dosing design at initial prescription increased significantly from 21% pre-intervention to 60% post-intervention (P < 0.01). The proportion of pharmacist intervention in initial dosing design increased over time. The proportion of patients with measured aminoglycoside blood concentrations significantly increased from 53% pre-intervention to 72% post-intervention (P < 0.01). The proportion of patients who were able to manage target blood concentrations from the initial aminoglycoside dose without dose adjustments increased from 31% pre-intervention to 42% post-intervention, although the results were not significantly different (P = 0.07). The incidence rate of renal impairment remained similar (11% vs. 12%; P = 0.85), although the annual average number of cases decreased from 4.3 before the intervention to 2.5 after. Similarly, there were no significant differences in clinical efficacy before and after the intervention (65% vs. 71%; P = 0.35). Furthermore, aminoglycoside stewardship led to a 56% cost saving.</p><p><strong>Conclusions: </strong>Pharmacist-led aminoglycoside stewardship significantly improved the appropriate use of aminoglycosides and decreased the associated costs. Thus, pharmacist involvement is essential for the proper use of aminoglycosides. However, many patients required aminoglycoside dose reductions despite the pharmacist's guideline-based dosing design. Therefore, further accumulation of information on the management of aminoglycoside blood concentration may be necessary for the revision of these guidelines.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"77"},"PeriodicalIF":1.2,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142750386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study. 阿司匹林和普拉格雷双重抗血小板疗法期间同时使用质子泵抑制剂与上消化道出血相关的风险:一项回顾性单中心研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-25 DOI: 10.1186/s40780-024-00398-y
Yutaro Ide, Go Morikawa, Kyohei Yoshida, Yuki Takano, Ken Kubota, Katsuko Okazawa, Takeo Yasu

Objective: Dual-antiplatelet therapy (DAPT) and proton pump inhibitor (PPI) are frequently prescribed after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) placement. However, studies that evaluate the optimal PPI when used as primary prevention in patients without a history of peptic ulcer disease or upper gastrointestinal bleeding (UGIB), particularly in the context of DAPT involving prasugrel, are lacking. This study aimed to assess the efficacy and safety of PPI use in preventing UGIB in this patient population.

Methods: This study included patients who underwent PCI with coronary stent placement for acute coronary syndrome or stable angina at our institution from January 2015 to December 2020. Eligible patients started DAPT with aspirin and prasugrel and concomitantly received PPI therapy (lansoprazole or esomeprazole), with a follow-up period of two years. The primary endpoint was UGIB incidence, diagnosed during follow-up, serving as an efficacy measure. Secondary endpoints included the assessment of major bleeding (as defined by the Thrombolysis in Myocardial Infarction major bleeding criteria) and clinically relevant non-major bleeding events. Safety outcomes focused on adverse event incidence attributable to PPI use.

Results: Among the 165 patients analyzed, 109 and 56 were included in the lansoprazole and esomeprazole groups, respectively, with cumulative incidence of UGIB at 96 weeks of 0.9% (1/109) and 3.6% (2/56). No significant differences in terms of major bleeding events or other bleeding outcomes were observed between the two groups. Adverse events related to PPI use were reported as diarrhea/soft stools in 7 (6%) cases and thrombocytopenia in 1 (1%) case in the lansoprazole group, whereas no such events were observed in the esomeprazole group. No clinically significant hematologic or biochemical abnormalities were reported.

Conclusion: This study evaluated the efficacy and safety of PPIs in combination with DAPT, including prasugrel, following PCI, and suggests that lansoprazole and esomeprazole may offer comparable efficacy in preventing UGIB.

目的:使用药物洗脱支架(DES)进行经皮冠状动脉介入治疗(PCI)后,双抗血小板疗法(DAPT)和质子泵抑制剂(PPI)是常用的处方药。然而,目前还缺乏对无消化性溃疡病史或上消化道出血(UGIB)史的患者进行一级预防时使用的最佳 PPI 进行评估的研究,尤其是在使用普拉格雷的 DAPT 时。本研究旨在评估使用 PPI 预防这类患者 UGIB 的有效性和安全性:本研究纳入了2015年1月至2020年12月期间在我院因急性冠脉综合征或稳定型心绞痛接受PCI并植入冠状动脉支架的患者。符合条件的患者开始使用阿司匹林和普拉格雷进行 DAPT,同时接受 PPI 治疗(兰索拉唑或埃索美拉唑),随访期为两年。主要终点是随访期间确诊的 UGIB 发生率,作为疗效衡量标准。次要终点包括评估大出血(根据心肌梗死溶栓治疗大出血标准定义)和临床相关的非大出血事件。安全性结果主要关注使用 PPI 引起的不良事件发生率:在分析的165例患者中,兰索拉唑组和埃索美拉唑组分别有109例和56例患者,96周时UGIB的累计发生率分别为0.9%(1/109)和3.6%(2/56)。两组在大出血事件或其他出血结果方面未发现明显差异。据报告,兰索拉唑组有7例(6%)腹泻/软便,1例(1%)血小板减少,而埃索美拉唑组未观察到与使用PPI相关的不良事件。未报告有临床意义的血液学或生化异常:本研究评估了PCI术后PPIs与包括普拉格雷在内的DAPT联用的疗效和安全性,结果表明兰索拉唑和埃索美拉唑在预防UGIB方面的疗效相当。
{"title":"The risk of upper gastrointestinal bleeding associated with concomitant proton pump inhibitor administration during dual antiplatelet therapy with aspirin and prasugrel: a retrospective single-center study.","authors":"Yutaro Ide, Go Morikawa, Kyohei Yoshida, Yuki Takano, Ken Kubota, Katsuko Okazawa, Takeo Yasu","doi":"10.1186/s40780-024-00398-y","DOIUrl":"10.1186/s40780-024-00398-y","url":null,"abstract":"<p><strong>Objective: </strong>Dual-antiplatelet therapy (DAPT) and proton pump inhibitor (PPI) are frequently prescribed after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) placement. However, studies that evaluate the optimal PPI when used as primary prevention in patients without a history of peptic ulcer disease or upper gastrointestinal bleeding (UGIB), particularly in the context of DAPT involving prasugrel, are lacking. This study aimed to assess the efficacy and safety of PPI use in preventing UGIB in this patient population.</p><p><strong>Methods: </strong>This study included patients who underwent PCI with coronary stent placement for acute coronary syndrome or stable angina at our institution from January 2015 to December 2020. Eligible patients started DAPT with aspirin and prasugrel and concomitantly received PPI therapy (lansoprazole or esomeprazole), with a follow-up period of two years. The primary endpoint was UGIB incidence, diagnosed during follow-up, serving as an efficacy measure. Secondary endpoints included the assessment of major bleeding (as defined by the Thrombolysis in Myocardial Infarction major bleeding criteria) and clinically relevant non-major bleeding events. Safety outcomes focused on adverse event incidence attributable to PPI use.</p><p><strong>Results: </strong>Among the 165 patients analyzed, 109 and 56 were included in the lansoprazole and esomeprazole groups, respectively, with cumulative incidence of UGIB at 96 weeks of 0.9% (1/109) and 3.6% (2/56). No significant differences in terms of major bleeding events or other bleeding outcomes were observed between the two groups. Adverse events related to PPI use were reported as diarrhea/soft stools in 7 (6%) cases and thrombocytopenia in 1 (1%) case in the lansoprazole group, whereas no such events were observed in the esomeprazole group. No clinically significant hematologic or biochemical abnormalities were reported.</p><p><strong>Conclusion: </strong>This study evaluated the efficacy and safety of PPIs in combination with DAPT, including prasugrel, following PCI, and suggests that lansoprazole and esomeprazole may offer comparable efficacy in preventing UGIB.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"76"},"PeriodicalIF":1.2,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587642/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-vivo evaluation of analgesic and anti-inflammatory activities of the 80% methanol extract of Acacia seyal stem bark in rodent models. 在啮齿动物模型中对相思树茎皮 80% 甲醇提取物的镇痛和抗炎活性进行体内评估。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-18 DOI: 10.1186/s40780-024-00387-1
Gena Kedir, Akeberegn Gorems Ayele, Workineh Shibeshi

Background: Pain and inflammation are the major medical condition commonly addressed with traditional remedies. Acacia seyal is a traditional herb widely used in Ethiopian folk medicine for pain management. However, its effectiveness has yet to be validated through scientific or experimental research. Therefore, the current study aims at evaluating the in vivo analgesic and anti-inflammatory effects of 80% methanolic stem bark extract of Acacia seyal in rodent models.

Methods: After successful extractions of the stem barks of Acacia seyal with 80% methanol, the pain relieving effects of 100, 200 and 400 mg/kg extract were evaluated using acetic acid-induced writhing test and hot plate method whereas the anti-inflammatory profile was determined by carrageenan induced paw-edema model and cotton pellet induced granuloma technique.

Results: The 80% methanol Acacia seyal stem bark extract exhibited substantial (p < 0.001) analgesic effect in acetic acid induced writing test (p < 0.001). The plant extract also witnessed significant central analgesic effect in hot plate method beginning at 30 min with maximum % elongation time occurred at 120 min. Furthermore, the acacia stem bark extract produced anti-inflammatory effect against carrageenan induced paw-edema model. In cotton pellet induced granuloma model, the 200 and 400 mg/kg doses of the current plant material appeared to inhibit granuloma mass formation and exudate reduction significantly (p < 0.001).

Conclusion: The collective findings of the current study revealed that 80% methanol extracts of Acacia seyal exhibited considerable analgesic and anti-inflammatory activities, supporting the plant's traditional use for management of pain and inflammatory disorders.

背景:疼痛和炎症是常用传统疗法治疗的主要病症。相思树是埃塞俄比亚民间医药中广泛用于止痛的一种传统草药。然而,其有效性还有待通过科学或实验研究来验证。因此,本研究旨在评估相思树茎皮 80% 甲醇提取物在啮齿动物模型中的体内镇痛和抗炎作用:方法:用80%的甲醇成功提取相思树茎皮后,采用醋酸诱导的蠕动试验和热板法评估100、200和400 mg/kg提取物的镇痛效果,同时采用卡拉胶诱导的爪水肿模型和棉球诱导的肉芽肿技术确定抗炎特征:结果:80%的甲醇相思树茎皮提取物表现出了很强的抗炎性(p 结论:80%的甲醇相思树茎皮提取物具有很强的抗炎性:本研究的综合结果表明,80% 的相思树甲醇提取物具有相当强的镇痛和抗炎活性,支持该植物用于治疗疼痛和炎症性疾病的传统用途。
{"title":"In-vivo evaluation of analgesic and anti-inflammatory activities of the 80% methanol extract of Acacia seyal stem bark in rodent models.","authors":"Gena Kedir, Akeberegn Gorems Ayele, Workineh Shibeshi","doi":"10.1186/s40780-024-00387-1","DOIUrl":"10.1186/s40780-024-00387-1","url":null,"abstract":"<p><strong>Background: </strong>Pain and inflammation are the major medical condition commonly addressed with traditional remedies. Acacia seyal is a traditional herb widely used in Ethiopian folk medicine for pain management. However, its effectiveness has yet to be validated through scientific or experimental research. Therefore, the current study aims at evaluating the in vivo analgesic and anti-inflammatory effects of 80% methanolic stem bark extract of Acacia seyal in rodent models.</p><p><strong>Methods: </strong>After successful extractions of the stem barks of Acacia seyal with 80% methanol, the pain relieving effects of 100, 200 and 400 mg/kg extract were evaluated using acetic acid-induced writhing test and hot plate method whereas the anti-inflammatory profile was determined by carrageenan induced paw-edema model and cotton pellet induced granuloma technique.</p><p><strong>Results: </strong>The 80% methanol Acacia seyal stem bark extract exhibited substantial (p < 0.001) analgesic effect in acetic acid induced writing test (p < 0.001). The plant extract also witnessed significant central analgesic effect in hot plate method beginning at 30 min with maximum % elongation time occurred at 120 min. Furthermore, the acacia stem bark extract produced anti-inflammatory effect against carrageenan induced paw-edema model. In cotton pellet induced granuloma model, the 200 and 400 mg/kg doses of the current plant material appeared to inhibit granuloma mass formation and exudate reduction significantly (p < 0.001).</p><p><strong>Conclusion: </strong>The collective findings of the current study revealed that 80% methanol extracts of Acacia seyal exhibited considerable analgesic and anti-inflammatory activities, supporting the plant's traditional use for management of pain and inflammatory disorders.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"75"},"PeriodicalIF":1.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11575448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of a melatonin receptor agonist and orexin receptor antagonists in preventing delirium symptoms in the olderly patients with stroke: a retrospective study. 褪黑激素受体激动剂和奥曲肽受体拮抗剂对预防老年中风患者谵妄症状的疗效:一项回顾性研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-18 DOI: 10.1186/s40780-024-00397-z
Yukiko Miyoshi, Yuki Shigetsura, Daiki Hira, Takakuni Maki, Hirotsugu Kawashima, Naoko Sugita, Noriko Sugawara, Noriaki Kitada, Machiko Hirai, Masayoshi Kawata, Hiroki Endo, Yusuke Kojima, Keiko Ikuta, Yurie Katsube, Natsuki Imayoshi, Shunsaku Nakagawa, Masahiro Tsuda, Tomohiro Terada

Background: Post-stroke delirium affects between 24% and 43% of patients, and negatively impacts patient outcomes. Recently, research attention has been on preventive interventions for delirium, with melatonin receptor agonists and orexin receptor antagonists reported to be effective in preventing delirium in intensive care unit patients. However, the efficacy of these agents in preventing post-stroke delirium remain unclear. This study examined the efficacy of ramelteon, suvorexant, and lemborexant in preventing post-stroke delirium symptoms in patients with stroke.

Methods: A retrospective survey of medical records was conducted for patients with stroke aged > 75 years at Kyoto University Hospital from October 2021 to March 2023. Patients who received ramelteon, suvorexant, or lemborexant on admission and the following day were classified into the consecutive administration group, whereas those who did not were classified into the non-consecutive administration group. The primary outcome was an increase in the number of positive items in the delirium screening tool over 7 days.

Results: Of the 104 patients, 33 and 71 were in the consecutive and non-consecutive administration groups, respectively. Fewer patients in the consecutive administration group had an increase in the number of positive items than in the other group (6% vs. 21%). Patients in the consecutive administration group significantly less often had an increase in the number of positive items in the delirium screening tool (P = 0.05; hazard ratio, 0.27; 95% confidence interval, 0.10-0.75).

Conclusions: This study revealed that early administration of a melatonin receptor agonist or orexin receptor antagonists may effectively prevent post-stroke delirium in older patients.

背景介绍24% 至 43% 的患者在中风后会出现谵妄,并对患者的预后产生负面影响。据报道,褪黑素受体激动剂和奥曲肽受体拮抗剂可有效预防重症监护室患者的谵妄。然而,这些药物对预防脑卒中后谵妄的疗效仍不明确。本研究探讨了雷美替翁、苏伏雷康和伦博雷康在预防脑卒中患者脑卒中后谵妄症状方面的疗效:方法:对京都大学医院 2021 年 10 月至 2023 年 3 月期间年龄大于 75 岁的脑卒中患者的病历进行了回顾性调查。将在入院时和次日接受雷美替胺、苏伏雷康或利博雷康治疗的患者划分为连续用药组,而未接受治疗的患者划分为非连续用药组。主要结果是 7 天内谵妄筛查工具中阳性项目数量的增加:在 104 名患者中,连续用药组和非连续用药组分别有 33 人和 71 人。与其他组相比,连续用药组中阳性项目数量增加的患者较少(6% 对 21%)。在谵妄筛查工具中,连续用药组患者阳性项目数增加的情况明显少于非连续用药组(P = 0.05;危险比为 0.27;95% 置信区间为 0.10-0.75):本研究表明,早期服用褪黑素受体激动剂或奥曲肽受体拮抗剂可有效预防老年患者卒中后谵妄。
{"title":"Efficacy of a melatonin receptor agonist and orexin receptor antagonists in preventing delirium symptoms in the olderly patients with stroke: a retrospective study.","authors":"Yukiko Miyoshi, Yuki Shigetsura, Daiki Hira, Takakuni Maki, Hirotsugu Kawashima, Naoko Sugita, Noriko Sugawara, Noriaki Kitada, Machiko Hirai, Masayoshi Kawata, Hiroki Endo, Yusuke Kojima, Keiko Ikuta, Yurie Katsube, Natsuki Imayoshi, Shunsaku Nakagawa, Masahiro Tsuda, Tomohiro Terada","doi":"10.1186/s40780-024-00397-z","DOIUrl":"10.1186/s40780-024-00397-z","url":null,"abstract":"<p><strong>Background: </strong>Post-stroke delirium affects between 24% and 43% of patients, and negatively impacts patient outcomes. Recently, research attention has been on preventive interventions for delirium, with melatonin receptor agonists and orexin receptor antagonists reported to be effective in preventing delirium in intensive care unit patients. However, the efficacy of these agents in preventing post-stroke delirium remain unclear. This study examined the efficacy of ramelteon, suvorexant, and lemborexant in preventing post-stroke delirium symptoms in patients with stroke.</p><p><strong>Methods: </strong>A retrospective survey of medical records was conducted for patients with stroke aged > 75 years at Kyoto University Hospital from October 2021 to March 2023. Patients who received ramelteon, suvorexant, or lemborexant on admission and the following day were classified into the consecutive administration group, whereas those who did not were classified into the non-consecutive administration group. The primary outcome was an increase in the number of positive items in the delirium screening tool over 7 days.</p><p><strong>Results: </strong>Of the 104 patients, 33 and 71 were in the consecutive and non-consecutive administration groups, respectively. Fewer patients in the consecutive administration group had an increase in the number of positive items than in the other group (6% vs. 21%). Patients in the consecutive administration group significantly less often had an increase in the number of positive items in the delirium screening tool (P = 0.05; hazard ratio, 0.27; 95% confidence interval, 0.10-0.75).</p><p><strong>Conclusions: </strong>This study revealed that early administration of a melatonin receptor agonist or orexin receptor antagonists may effectively prevent post-stroke delirium in older patients.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"74"},"PeriodicalIF":1.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study on the chemical stability of β-lactam antibiotics in concomitant simple suspensions with magnesium oxide. 研究β-内酰胺类抗生素在与氧化镁混合的简单悬浮液中的化学稳定性。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-18 DOI: 10.1186/s40780-024-00396-0
Ginjiro Kato, Hidemichi Mitome, Syu Takeda, Noriaki Hidaka, Mamoru Tanaka, Kazuki Akira

Background: A simple suspension method, where solid formulations are disintegrated and suspended by being soaked in warm water followed by tube administration, is widely used, especially for elderly patients with dysphagia in Japanese clinical settings. However, there is insufficient information on drug stability in the simple co-suspension of multiple formulations especially including acidic or alkaline ones. The influence of occasional prolonged soakage on drug stability is also of concern. In this study, the chemical stability of typical β-lactam antibiotics, amoxicillin, and cefcapene pivoxil hydrochloride, was investigated in simple co-suspensions with magnesium oxide (MgO), which is frequently used as an alkaline laxative for the elderly.

Methods: Amoxicillin (capsule) or cefcapene pivoxil hydrochloride (tablet) was placed with or without MgO (tablet) in a centrifuge tube containing warm water (55 °C). The tube was allowed to stand for 10 min or 5 h at room temperature and simple suspensions were prepared. The suspensions were then treated with large amounts of solvents and neutralized using a weakly acidic cation exchange resin. The resulting solutions were analyzed by high-performance liquid chromatography. The degradation products were identified by mass spectrometry and nuclear magnetic resonance spectroscopy.

Results: Amoxicillin was found to be partially degraded to amoxicilloic acid and amoxicillin diketopiperazine by the co-suspension with MgO. The degree of degradation increased with the prolonged soaking. The recovery rates of cefcapene pivoxil decreased due to the poor solubility in the co-suspensions with MgO and no degradation product of the drug was observed.

Conclusions: Amoxicillin and MgO should be independently suspended because of the chemical instability of amoxicillin. This study has also indicated there is a degradation risk after prolonged soaking. It should be noted that the poor water solubility of cefcapene pivoxil under alkaline conditions may affect the absorption process as well as tube passability.

背景:简单混悬法是指将固体制剂在温水中浸泡,使其崩解并悬浮,然后进行管式给药,这种方法被广泛使用,尤其是在日本的临床环境中用于吞咽困难的老年患者。然而,关于多种制剂(尤其是酸性或碱性制剂)简单共悬浮时的药物稳定性,目前还没有足够的资料。偶尔长时间浸泡对药物稳定性的影响也值得关注。本研究调查了典型的β-内酰胺类抗生素阿莫西林和盐酸头孢卡品酯在与氧化镁(MgO)简单共混悬浮液中的化学稳定性:方法:将阿莫西林(胶囊)或盐酸头孢卡品酯片(片剂)与或不与氧化镁(片剂)一起放入装有温水(55 °C)的离心管中。将离心管在室温下放置 10 分钟或 5 小时,制备简单的悬浮液。然后用大量溶剂处理悬浮液,并用弱酸性阳离子交换树脂中和。所得溶液通过高效液相色谱法进行分析。降解产物通过质谱和核磁共振光谱进行鉴定:结果:发现阿莫西林在与氧化镁共悬浮后部分降解为阿莫西林酸和阿莫西林二酮哌嗪。降解程度随着浸泡时间的延长而增加。由于头孢卡品酯在与氧化镁共混悬浮液中的溶解度较低,因此头孢卡品酯的回收率下降,而且没有观察到药物的降解产物:结论:由于阿莫西林的化学性质不稳定,阿莫西林和氧化镁应独立悬浮。结论:由于阿莫西林的化学性质不稳定,因此阿莫西林和氧化镁应独立悬浮。这项研究还表明,阿莫西林在长时间浸泡后有降解的风险。值得注意的是,头孢卡品酯在碱性条件下的水溶性较差,可能会影响吸收过程和试管通过性。
{"title":"Study on the chemical stability of β-lactam antibiotics in concomitant simple suspensions with magnesium oxide.","authors":"Ginjiro Kato, Hidemichi Mitome, Syu Takeda, Noriaki Hidaka, Mamoru Tanaka, Kazuki Akira","doi":"10.1186/s40780-024-00396-0","DOIUrl":"10.1186/s40780-024-00396-0","url":null,"abstract":"<p><strong>Background: </strong>A simple suspension method, where solid formulations are disintegrated and suspended by being soaked in warm water followed by tube administration, is widely used, especially for elderly patients with dysphagia in Japanese clinical settings. However, there is insufficient information on drug stability in the simple co-suspension of multiple formulations especially including acidic or alkaline ones. The influence of occasional prolonged soakage on drug stability is also of concern. In this study, the chemical stability of typical β-lactam antibiotics, amoxicillin, and cefcapene pivoxil hydrochloride, was investigated in simple co-suspensions with magnesium oxide (MgO), which is frequently used as an alkaline laxative for the elderly.</p><p><strong>Methods: </strong>Amoxicillin (capsule) or cefcapene pivoxil hydrochloride (tablet) was placed with or without MgO (tablet) in a centrifuge tube containing warm water (55 °C). The tube was allowed to stand for 10 min or 5 h at room temperature and simple suspensions were prepared. The suspensions were then treated with large amounts of solvents and neutralized using a weakly acidic cation exchange resin. The resulting solutions were analyzed by high-performance liquid chromatography. The degradation products were identified by mass spectrometry and nuclear magnetic resonance spectroscopy.</p><p><strong>Results: </strong>Amoxicillin was found to be partially degraded to amoxicilloic acid and amoxicillin diketopiperazine by the co-suspension with MgO. The degree of degradation increased with the prolonged soaking. The recovery rates of cefcapene pivoxil decreased due to the poor solubility in the co-suspensions with MgO and no degradation product of the drug was observed.</p><p><strong>Conclusions: </strong>Amoxicillin and MgO should be independently suspended because of the chemical instability of amoxicillin. This study has also indicated there is a degradation risk after prolonged soaking. It should be noted that the poor water solubility of cefcapene pivoxil under alkaline conditions may affect the absorption process as well as tube passability.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"73"},"PeriodicalIF":1.2,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer. 小剂量泼尼松龙加醋酸阿比特龙治疗转移性阉割耐药前列腺癌引起的低钾血症的兼容性。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-11 DOI: 10.1186/s40780-024-00391-5
Shota Torii, Aya Torii-Goto, Tamaki Tanizawa, Takashi Sakakibara, Ryosuke Oguri, Haruka Nagase, Yuri Nakao, Tomoyuki Hirashita, Kuniaki Tanaka, Norio Takimoto, Takahiro Hayashi

Background: This study aimed to investigate the relationship between low-dose prednisolone (PSL) and the incidence of hypokalaemia at abiraterone acetate (abiraterone) plus PSL combination therapy targeting Japanese patients with metastatic castration-resistant prostate cancer (mCRPC).

Methods: This retrospective observational study included 153 Japanese patients treated with abiraterone and PSL for mCRPC at Kariya Toyota General Hospital and Gifu General Medical Center between September 2014 and October 2022. The incidence of grade ≥ 2 hypokalaemia as well as serum potassium level variations and the continuous combination therapy duration were compared between the low-dose (5 mg/day of PSL) and the standard-dose (10 mg/day of PSL) groups.

Results: This study included 153 patient of which 95 were matched to establish the analysis population. The low-dose and the standard-dose groups consisted of 13 and 82 patients, respectively. No significant difference in the incidence of grade ≥ 2 hypokalaemia was observed between the two groups [15.4% (2/13 patients) in the low-dose group and 12.2% (10/82 patients) in the standard-dose group, P = 0.667]. The low-dose group exhibited a decrease in serum potassium levels from 4.63 on day - 7 - 0 to 4.16 mmol/L on day 84 ± 10 (n = 7, P = 0.066), and serum potassium levels from day - 7 - 0 to 84 ± 10 in the low-dose group appeared to be great in the standard-dose group (n = 37, P = 0.475). The Kaplan-Meier curves for continuity of abiraterone and PSL therapy were not significantly different between the low-dose group (n = 13) and standard-dose group (n = 82, P = 0.427).

Conclusion: Combination therapy with abiraterone and 5 mg/day of PSL in Japanese patients with mCRPC did not change the incidence of grade ≥ 2 hypokalaemia. However, although not significant, 5 mg/day of PSL demonstrated a decreasing trend in serum potassium levels with a larger degree of change than that of 10 mg/day of PSL. Therefore, the combination of abiraterone and 5 mg/day PSL can be administered to Japanese patients with mCRPC. The patients must be monitored for hypokalaemia through measurement of serum potassium levels and observation of subjective symptoms such as muscle weakness, convulsion etc. In addition, the doctor or the pharmacist must explain these symptoms to the patient and instruct them to consult their medical staff immediately in the event of development of such symptoms.

研究背景本研究旨在调查低剂量泼尼松龙(PSL)与醋酸阿比特龙(abiraterone acetate,阿比特龙)加 PSL 联合疗法中低钾血症发生率之间的关系,研究对象为日本转移性耐阉割前列腺癌(mCRPC)患者:这项回顾性观察研究纳入了2014年9月至2022年10月期间在刈谷丰田综合医院和岐阜综合医疗中心接受阿比特龙和PSL治疗的153名mCRPC日本患者。比较了低剂量组(PSL 5 毫克/天)和标准剂量组(PSL 10 毫克/天)的≥2 级低钾血症发生率、血清钾水平变化以及持续联合治疗时间:本研究共纳入 153 例患者,其中 95 例为配对患者。低剂量组和标准剂量组分别有 13 名和 82 名患者。两组间≥2级低钾血症的发生率无明显差异[低剂量组为15.4%(2/13例患者),标准剂量组为12.2%(10/82例患者),P = 0.667]。低剂量组的血清钾水平从第 7 - 0 天的 4.63 降至第 84 ± 10 天的 4.16 mmol/L(n = 7,P = 0.066),而低剂量组从第 7 - 0 天到第 84 ± 10 天的血清钾水平似乎比标准剂量组高(n = 37,P = 0.475)。低剂量组(n = 13)和标准剂量组(n = 82,P = 0.427)阿比特龙和 PSL 治疗持续性的 Kaplan-Meier 曲线无显著差异:结论:日本mCRPC患者接受阿比特龙和5毫克/天PSL联合治疗不会改变≥2级低钾血症的发生率。不过,尽管不显著,但每天 5 毫克的 PSL 显示血清钾水平呈下降趋势,且变化程度大于每天 10 毫克的 PSL。因此,日本的 mCRPC 患者可以联合使用阿比特龙和每天 5 毫克的 PSL。必须通过测量血清钾水平和观察肌肉无力、抽搐等主观症状来监测患者是否出现低钾血症。此外,医生或药剂师必须向患者解释这些症状,并指示他们在出现这些症状时立即咨询医务人员。
{"title":"Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer.","authors":"Shota Torii, Aya Torii-Goto, Tamaki Tanizawa, Takashi Sakakibara, Ryosuke Oguri, Haruka Nagase, Yuri Nakao, Tomoyuki Hirashita, Kuniaki Tanaka, Norio Takimoto, Takahiro Hayashi","doi":"10.1186/s40780-024-00391-5","DOIUrl":"10.1186/s40780-024-00391-5","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the relationship between low-dose prednisolone (PSL) and the incidence of hypokalaemia at abiraterone acetate (abiraterone) plus PSL combination therapy targeting Japanese patients with metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Methods: </strong>This retrospective observational study included 153 Japanese patients treated with abiraterone and PSL for mCRPC at Kariya Toyota General Hospital and Gifu General Medical Center between September 2014 and October 2022. The incidence of grade ≥ 2 hypokalaemia as well as serum potassium level variations and the continuous combination therapy duration were compared between the low-dose (5 mg/day of PSL) and the standard-dose (10 mg/day of PSL) groups.</p><p><strong>Results: </strong>This study included 153 patient of which 95 were matched to establish the analysis population. The low-dose and the standard-dose groups consisted of 13 and 82 patients, respectively. No significant difference in the incidence of grade ≥ 2 hypokalaemia was observed between the two groups [15.4% (2/13 patients) in the low-dose group and 12.2% (10/82 patients) in the standard-dose group, P = 0.667]. The low-dose group exhibited a decrease in serum potassium levels from 4.63 on day - 7 - 0 to 4.16 mmol/L on day 84 ± 10 (n = 7, P = 0.066), and serum potassium levels from day - 7 - 0 to 84 ± 10 in the low-dose group appeared to be great in the standard-dose group (n = 37, P = 0.475). The Kaplan-Meier curves for continuity of abiraterone and PSL therapy were not significantly different between the low-dose group (n = 13) and standard-dose group (n = 82, P = 0.427).</p><p><strong>Conclusion: </strong>Combination therapy with abiraterone and 5 mg/day of PSL in Japanese patients with mCRPC did not change the incidence of grade ≥ 2 hypokalaemia. However, although not significant, 5 mg/day of PSL demonstrated a decreasing trend in serum potassium levels with a larger degree of change than that of 10 mg/day of PSL. Therefore, the combination of abiraterone and 5 mg/day PSL can be administered to Japanese patients with mCRPC. The patients must be monitored for hypokalaemia through measurement of serum potassium levels and observation of subjective symptoms such as muscle weakness, convulsion etc. In addition, the doctor or the pharmacist must explain these symptoms to the patient and instruct them to consult their medical staff immediately in the event of development of such symptoms.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"72"},"PeriodicalIF":1.2,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11552156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A qualitative study on the current status and problems of pharmacists in home healthcare from the viewpoint of care managers in medically underpopulated areas in Japan. 从日本医疗人口不足地区护理管理者的角度,对家庭保健中药剂师的现状和问题进行定性研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-08 DOI: 10.1186/s40780-024-00395-1
Yuji Nakagawa, Hideo Kato, Takuya Iwamoto

Background: Unlike in urban areas, community healthcare in medically underpopulated areas in Japan is constantly challenged because of the uncertainty in effectively using the limited resources. However, no study has focused on human resources or identified the actual state of pharmacists' support in the community. Therefore, our study identified the actual status and problems of pharmacists involved in home medical care in medically underpopulated areas and discussed the roles required of pharmacists and specific methods of support.

Methods: The content of semi-structured interviews with care managers involved in home healthcare in Misugi town, Tsu City, between November 10, 2023 and March 13, 2024, was analyzed qualitatively using the grounded theory approach.

Results: Five care managers participated in the study. Semi-structured interviews on the actual situation and challenges faced by pharmacists indicated that the following roles were required for pharmacists: as in other regions, it was observed that elderly people with dementia and those living alone managed their medicines, adjusted leftover medicines, collaborated with other professions, bridged with physicians, checked medication status through frequent visits, and adhered to internal medication regimens. Issues related to the characteristics of depopulated areas were identified including human resources, limitations of healthcare resources, economic burden, limits on the number of visits by pharmacists. As a characteristic of communities with no pharmacies and only in-hospital prescribing, pharmacists were expected by care managers to manage the problems caused by in-hospital prescribing.

Conclusions: Our findings suggest that pharmacists should ensure the number of visits and collaborate with attending physicians, visiting nurses, and care managers to conduct drug management for patients with dementia and older adults living alone. Community healthcare specialists and those involved in the healthcare planning system can also utilize these findings while planning home healthcare to those who live in medically underpopulated areas in Japan.

背景:与城市地区不同,日本医疗人口不足地区的社区医疗保健一直面临挑战,因为有限的资源无法得到有效利用。然而,还没有研究关注人力资源或确定药剂师在社区提供支持的实际状况。因此,我们的研究确定了药剂师在医疗人口不足地区参与家庭医疗护理的实际状况和问题,并讨论了药剂师所需的角色和具体的支持方法:方法:采用基础理论方法,对 2023 年 11 月 10 日至 2024 年 3 月 13 日期间津市三杉町从事居家医疗的护理经理进行的半结构式访谈内容进行定性分析:结果:五名护理经理参与了研究。就药剂师的实际情况和面临的挑战进行的半结构化访谈表明,药剂师需要扮演以下角色:与其他地区一样,观察到失智症老人和独居老人管理自己的药物、调整剩余药物、与其他专业人员合作、与医生沟通、通过频繁访问检查用药情况以及坚持内部用药方案。与人口稀少地区的特点相关的问题包括人力资源、医疗保健资源的限制、经济负担、药剂师上门服务次数的限制等。作为没有药房和只有院内处方的社区的一个特点,护理管理者希望药剂师能够管理院内处方引起的问题:我们的研究结果表明,药剂师应确保出诊次数,并与主治医生、出诊护士和护理经理合作,对痴呆症患者和独居老年人进行药物管理。社区医疗保健专家和医疗保健规划系统的相关人员在为日本医疗人口不足地区的居民规划家庭医疗保健时,也可以利用这些研究结果。
{"title":"A qualitative study on the current status and problems of pharmacists in home healthcare from the viewpoint of care managers in medically underpopulated areas in Japan.","authors":"Yuji Nakagawa, Hideo Kato, Takuya Iwamoto","doi":"10.1186/s40780-024-00395-1","DOIUrl":"10.1186/s40780-024-00395-1","url":null,"abstract":"<p><strong>Background: </strong>Unlike in urban areas, community healthcare in medically underpopulated areas in Japan is constantly challenged because of the uncertainty in effectively using the limited resources. However, no study has focused on human resources or identified the actual state of pharmacists' support in the community. Therefore, our study identified the actual status and problems of pharmacists involved in home medical care in medically underpopulated areas and discussed the roles required of pharmacists and specific methods of support.</p><p><strong>Methods: </strong>The content of semi-structured interviews with care managers involved in home healthcare in Misugi town, Tsu City, between November 10, 2023 and March 13, 2024, was analyzed qualitatively using the grounded theory approach.</p><p><strong>Results: </strong>Five care managers participated in the study. Semi-structured interviews on the actual situation and challenges faced by pharmacists indicated that the following roles were required for pharmacists: as in other regions, it was observed that elderly people with dementia and those living alone managed their medicines, adjusted leftover medicines, collaborated with other professions, bridged with physicians, checked medication status through frequent visits, and adhered to internal medication regimens. Issues related to the characteristics of depopulated areas were identified including human resources, limitations of healthcare resources, economic burden, limits on the number of visits by pharmacists. As a characteristic of communities with no pharmacies and only in-hospital prescribing, pharmacists were expected by care managers to manage the problems caused by in-hospital prescribing.</p><p><strong>Conclusions: </strong>Our findings suggest that pharmacists should ensure the number of visits and collaborate with attending physicians, visiting nurses, and care managers to conduct drug management for patients with dementia and older adults living alone. Community healthcare specialists and those involved in the healthcare planning system can also utilize these findings while planning home healthcare to those who live in medically underpopulated areas in Japan.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"71"},"PeriodicalIF":1.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of famotidine use during pregnancy: an observational cohort study. 孕期使用法莫替丁的影响:一项观察性队列研究。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-08 DOI: 10.1186/s40780-024-00393-3
Ayako Nishimura, Ayako Furugen, Masaki Kobayashi, Yoh Takekuma, Naho Yakuwa, Mikako Goto, Masahiro Hayashi, Atsuko Murashima, Mitsuru Sugawara

Background: Famotidine, a histamine2-receptor antagonist (H2Ras), is widely used to treat and prevent gastrointestinal symptoms during pregnancy. Although several studies have reported the use of H2Ras during pregnancy, limited data on famotidine were included in these reports. Therefore, we analyzed pregnancy outcome data to evaluate the effects of famotidine use during pregnancy on the fetus.

Methods: Pregnancy outcome data were used for females enrolled in two Japanese facilities that provided counseling on drug use during pregnancy between April 1988 and December 2017. For the primary endpoint, the incidence of congenital malformations was calculated from the data of live birth to pregnant women who took famotidine (n = 330) or drugs considered to exert no teratogenic risk (control, n = 1,407) during the first trimester of pregnancy. Considering secondary endpoints, the incidence of obstetric outcomes, including preterm delivery, was calculated from data on the use of famotidine (n = 347) and controls (n = 1,476) during the entire pregnancy. The crude odds ratios (cORs) for the incidence of congenital malformations were calculated using univariate logistic regression analysis, with the control group used as the reference. Adjusted ORs (aORs) were calculated using multivariate logistic regression analysis adjusted for various other factors.

Results: The incidences of congenital malformations in the famotidine and control groups were 3.9% and 2.8%, respectively. There was no significant difference between the famotidine and control groups (cOR: 1.40 [95% CI:0.68-2.71], aOR: 1.06 [95% CI:0.51-2.16]). Conversely, the preterm delivery rates were 8.1% and 3.8% in the famotidine and control groups, respectively, indicating a significant difference (cOR: 2.00 [95% CI:1.20-3.27]). However, the multivariate analysis eliminated famotidine use as a confounding factor.

Conclusions: This observational cohort study revealed that exposure to famotidine during the first trimester of pregnancy was not associated with an increased risk of congenital malformations in infants. Although a higher rate of preterm delivery was detected in famotidine users when compared with controls, this could be attributed to confounding factors, such as complications.

背景:法莫替丁是一种组胺2受体拮抗剂(H2Ras),被广泛用于治疗和预防孕期胃肠道症状。尽管有多项研究报告了妊娠期使用 H2Ras 的情况,但这些报告中关于法莫替丁的数据有限。因此,我们分析了妊娠结局数据,以评估孕期使用法莫替丁对胎儿的影响:妊娠结局数据用于1988年4月至2017年12月期间在日本两家提供孕期用药咨询的机构登记的女性。在主要终点方面,根据妊娠前三个月服用法莫替丁(n = 330)或被认为无致畸风险药物(对照组,n = 1 407)的孕妇的活产数据计算先天性畸形的发生率。考虑到次要终点,根据整个孕期服用法莫替丁(n = 347)和对照组(n = 1 476)的数据,计算了包括早产在内的产科结局发生率。先天性畸形发生率的粗略几率(cORs)采用单变量逻辑回归分析法计算,对照组作为参照。使用多变量逻辑回归分析计算调整后的几率比(aORs),并对其他各种因素进行调整:法莫替丁组和对照组的先天性畸形发生率分别为 3.9% 和 2.8%。法莫替丁组和对照组之间没有明显差异(cOR:1.40 [95% CI:0.68-2.71],aOR:1.06 [95% CI:0.51-2.16])。相反,法莫替丁组和对照组的早产率分别为 8.1%和 3.8%,差异显著(cOR:2.00 [95% CI:1.20-3.27])。然而,多变量分析排除了使用法莫替丁的混杂因素:这项观察性队列研究显示,妊娠头三个月期间接触法莫替丁与婴儿先天性畸形风险增加无关。虽然与对照组相比,法莫替丁使用者的早产率较高,但这可能是并发症等混杂因素造成的。
{"title":"Effects of famotidine use during pregnancy: an observational cohort study.","authors":"Ayako Nishimura, Ayako Furugen, Masaki Kobayashi, Yoh Takekuma, Naho Yakuwa, Mikako Goto, Masahiro Hayashi, Atsuko Murashima, Mitsuru Sugawara","doi":"10.1186/s40780-024-00393-3","DOIUrl":"10.1186/s40780-024-00393-3","url":null,"abstract":"<p><strong>Background: </strong>Famotidine, a histamine2-receptor antagonist (H2Ras), is widely used to treat and prevent gastrointestinal symptoms during pregnancy. Although several studies have reported the use of H2Ras during pregnancy, limited data on famotidine were included in these reports. Therefore, we analyzed pregnancy outcome data to evaluate the effects of famotidine use during pregnancy on the fetus.</p><p><strong>Methods: </strong>Pregnancy outcome data were used for females enrolled in two Japanese facilities that provided counseling on drug use during pregnancy between April 1988 and December 2017. For the primary endpoint, the incidence of congenital malformations was calculated from the data of live birth to pregnant women who took famotidine (n = 330) or drugs considered to exert no teratogenic risk (control, n = 1,407) during the first trimester of pregnancy. Considering secondary endpoints, the incidence of obstetric outcomes, including preterm delivery, was calculated from data on the use of famotidine (n = 347) and controls (n = 1,476) during the entire pregnancy. The crude odds ratios (cORs) for the incidence of congenital malformations were calculated using univariate logistic regression analysis, with the control group used as the reference. Adjusted ORs (aORs) were calculated using multivariate logistic regression analysis adjusted for various other factors.</p><p><strong>Results: </strong>The incidences of congenital malformations in the famotidine and control groups were 3.9% and 2.8%, respectively. There was no significant difference between the famotidine and control groups (cOR: 1.40 [95% CI:0.68-2.71], aOR: 1.06 [95% CI:0.51-2.16]). Conversely, the preterm delivery rates were 8.1% and 3.8% in the famotidine and control groups, respectively, indicating a significant difference (cOR: 2.00 [95% CI:1.20-3.27]). However, the multivariate analysis eliminated famotidine use as a confounding factor.</p><p><strong>Conclusions: </strong>This observational cohort study revealed that exposure to famotidine during the first trimester of pregnancy was not associated with an increased risk of congenital malformations in infants. Although a higher rate of preterm delivery was detected in famotidine users when compared with controls, this could be attributed to confounding factors, such as complications.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"70"},"PeriodicalIF":1.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and validation of the prediction score for augmented renal clearance in critically Ill Japanese adults. 重症日本成人肾清除率增强预测评分的开发与验证。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-06 DOI: 10.1186/s40780-024-00394-2
Ryusei Mikami, Shungo Imai, Mineji Hayakawa, Hitoshi Kashiwagi, Yuki Sato, Shunsuke Nashimoto, Mitsuru Sugawara, Yoh Takekuma

Background: Augmented renal clearance (ARC) decreases the therapeutic concentration of drugs excreted by the kidneys in critically ill patients. Several ARC prediction models have been developed and validated; however, their usefulness in Japan has not been comprehensively investigated. Thus, we developed a unique ARC prediction model for a Japanese mixed intensive care unit (ICU) population and compared it with existing models.

Methods: This retrospective study enrolled a mixed ICU population in Japan from January 2019 and June 2022. The primary outcome was the development and validation of a model to predict ARC onset based on baseline information at ICU admission. Patients admitted until May 2021 were included in the training set, and external validation was performed on patients admitted thereafter. A multivariate logistic regression model was used to develop an integer-based predictive scoring system for ARC. The new model (the JPNARC score) was externally validated along with the ARC and Augmented Renal Clearance in Trauma Intensive Care (ARCTIC) scores.

Results: A total of 2,592 critically ill patients were enrolled initially, with 651 patients finally included after excluding 1,941 patients. The training and validation datasets comprised 456 and 195 patients, respectively. Multivariate analysis was performed to develop the JPNARC score, which incorporated age, sex, serum creatinine, and diagnosis upon ICU admission (trauma or central nervous system disease). The JPNARC score had a larger area under the receiver operating characteristic curve than the ARC and ARCTIC scores in the validation dataset (0.832, 0.633, and 0.740, respectively).

Conclusions: An integer-based scoring system was developed to predict ARC onset in a critically ill Japanese population and showed high predictive performance. New models designed to predict the often-unrecognized ARC phenomenon may aid in the decision-making process for upward drug dosage modifications, especially in resource- and labor-limited settings.

背景:肾清除率增高(ARC)会降低重症患者肾脏排泄药物的治疗浓度。目前已开发并验证了多个 ARC 预测模型,但这些模型在日本的实用性尚未得到全面研究。因此,我们针对日本重症监护病房(ICU)的混合人群开发了一种独特的 ARC 预测模型,并将其与现有模型进行了比较:这项回顾性研究在 2019 年 1 月至 2022 年 6 月期间对日本的混合重症监护病房人群进行了登记。主要结果是开发并验证了一个基于 ICU 入院时的基线信息预测 ARC 发病的模型。2021年5月之前入院的患者被纳入训练集,之后入院的患者进行了外部验证。采用多元逻辑回归模型开发了基于整数的 ARC 预测评分系统。新模型(JPNARC评分)与ARC评分和创伤重症监护中增强肾清除率(ARCTIC)评分一起进行了外部验证:最初共有 2,592 名重症患者加入,在排除了 1,941 名患者后,最终纳入了 651 名患者。训练数据集和验证数据集分别包括 456 名和 195 名患者。通过多变量分析得出了 JPNARC 评分,其中包括年龄、性别、血清肌酐和入住 ICU 时的诊断(创伤或中枢神经系统疾病)。在验证数据集中,JPNARC评分的接收器操作特征曲线下面积大于ARC和ARCTIC评分(分别为0.832、0.633和0.740):结论:研究人员开发了一种基于整数的评分系统来预测日本重症患者的 ARC 发病情况,该系统具有很高的预测性能。旨在预测常被忽视的 ARC 现象的新模型可能有助于上调药物剂量的决策过程,尤其是在资源和劳动力有限的情况下。
{"title":"Development and validation of the prediction score for augmented renal clearance in critically Ill Japanese adults.","authors":"Ryusei Mikami, Shungo Imai, Mineji Hayakawa, Hitoshi Kashiwagi, Yuki Sato, Shunsuke Nashimoto, Mitsuru Sugawara, Yoh Takekuma","doi":"10.1186/s40780-024-00394-2","DOIUrl":"10.1186/s40780-024-00394-2","url":null,"abstract":"<p><strong>Background: </strong>Augmented renal clearance (ARC) decreases the therapeutic concentration of drugs excreted by the kidneys in critically ill patients. Several ARC prediction models have been developed and validated; however, their usefulness in Japan has not been comprehensively investigated. Thus, we developed a unique ARC prediction model for a Japanese mixed intensive care unit (ICU) population and compared it with existing models.</p><p><strong>Methods: </strong>This retrospective study enrolled a mixed ICU population in Japan from January 2019 and June 2022. The primary outcome was the development and validation of a model to predict ARC onset based on baseline information at ICU admission. Patients admitted until May 2021 were included in the training set, and external validation was performed on patients admitted thereafter. A multivariate logistic regression model was used to develop an integer-based predictive scoring system for ARC. The new model (the JPNARC score) was externally validated along with the ARC and Augmented Renal Clearance in Trauma Intensive Care (ARCTIC) scores.</p><p><strong>Results: </strong>A total of 2,592 critically ill patients were enrolled initially, with 651 patients finally included after excluding 1,941 patients. The training and validation datasets comprised 456 and 195 patients, respectively. Multivariate analysis was performed to develop the JPNARC score, which incorporated age, sex, serum creatinine, and diagnosis upon ICU admission (trauma or central nervous system disease). The JPNARC score had a larger area under the receiver operating characteristic curve than the ARC and ARCTIC scores in the validation dataset (0.832, 0.633, and 0.740, respectively).</p><p><strong>Conclusions: </strong>An integer-based scoring system was developed to predict ARC onset in a critically ill Japanese population and showed high predictive performance. New models designed to predict the often-unrecognized ARC phenomenon may aid in the decision-making process for upward drug dosage modifications, especially in resource- and labor-limited settings.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"69"},"PeriodicalIF":1.2,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142590682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice. 研究氟喹诺酮类抗菌药对非细菌性发热模型小鼠的低体温效应。
IF 1.2 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-11-04 DOI: 10.1186/s40780-024-00392-4
Ryohei Hara, Kazuaki Taguchi, Hiromi Ogino, Yuko Okamoto, Yuki Enoki, Junko Kizu, Seiji Hori, Kazuaki Matsumoto

Background: Fluoroquinolone (FQ) antimicrobials have antipyretic effects during the treatment of bacterial infections; however, it is not clear whether these are due to their antimicrobial activities or their hypothermic effects. In this study, we investigated the hypothermic effects of FQ antimicrobials (ciprofloxacin [CPFX], gatifloxacin [GFLX], and levofloxacin [LVFX]) on fever by evaluating rectal body temperature changes in a mouse model of non-bacterial fever.

Methods: CPFX, GFLX, and LVFX were administered intraperitoneally to non-bacterial fever model mice induced by yeast. Rectal body temperature was measured up to 180 min after administration.

Results: A decrease in rectal body temperature of up to 1.2 °C for CPFX, 3.4 °C for GFLX, and 1.0 °C for LVFX was observed. The decrease in temperature was induced by an increase in the plasma concentration of FQ antimicrobials, suggesting that they are responsible for the temperature reduction. Focusing on glucocorticoids, one thermoregulation mechanism, we investigated the substances responsible for the reduction in rectal body temperature induced by FQ antimicrobials. Aminoglutethimide (an inhibitor of glucocorticoid production) were premedicated, followed by intraperitoneal administration of GFLX in the yeast-induced fever mouse model, resulting in attenuated GFLX-induced hypothermic effects.

Conclusions: These results suggest that certain antipyretic effects of CPFX, GFPX, and LVFX during fever may contribute to their hypothermic effects; certain mechanisms are glucocorticoid-mediated.

背景:氟喹诺酮类(FQ)抗菌药在治疗细菌感染时具有解热作用;然而,目前尚不清楚这些作用是由于其抗菌活性还是由于其低温效应。在本研究中,我们通过评估非细菌性发热小鼠模型的直肠体温变化,研究了 FQ 类抗菌药物(环丙沙星 [CPFX]、加替沙星 [GFLX] 和左氧氟沙星 [LVFX])对发热的降温作用:方法: 对酵母菌诱导的非细菌性发热模型小鼠腹腔注射 CPFX、GFLX 和 LVFX。给药后 180 分钟测量直肠体温:结果:CPFX、GFLX 和 LVFX 的直肠体温分别下降了 1.2 ℃、3.4 ℃ 和 1.0 ℃。FQ抗菌药血浆浓度的增加诱导了体温的降低,这表明它们是体温降低的原因。我们以糖皮质激素这一体温调节机制为重点,研究了导致 FQ 抗菌剂诱导直肠体温降低的物质。在酵母菌诱导的发热小鼠模型中,先给氨丁三醇(糖皮质激素分泌抑制剂)预处理,然后腹腔给药 GFLX,结果 GFLX 诱导的低体温效应减弱:这些结果表明,CPFX、GFPX 和 LVFX 在发热期间的某些解热作用可能有助于它们的低体温效应;某些机制是糖皮质激素介导的。
{"title":"Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice.","authors":"Ryohei Hara, Kazuaki Taguchi, Hiromi Ogino, Yuko Okamoto, Yuki Enoki, Junko Kizu, Seiji Hori, Kazuaki Matsumoto","doi":"10.1186/s40780-024-00392-4","DOIUrl":"10.1186/s40780-024-00392-4","url":null,"abstract":"<p><strong>Background: </strong>Fluoroquinolone (FQ) antimicrobials have antipyretic effects during the treatment of bacterial infections; however, it is not clear whether these are due to their antimicrobial activities or their hypothermic effects. In this study, we investigated the hypothermic effects of FQ antimicrobials (ciprofloxacin [CPFX], gatifloxacin [GFLX], and levofloxacin [LVFX]) on fever by evaluating rectal body temperature changes in a mouse model of non-bacterial fever.</p><p><strong>Methods: </strong>CPFX, GFLX, and LVFX were administered intraperitoneally to non-bacterial fever model mice induced by yeast. Rectal body temperature was measured up to 180 min after administration.</p><p><strong>Results: </strong>A decrease in rectal body temperature of up to 1.2 °C for CPFX, 3.4 °C for GFLX, and 1.0 °C for LVFX was observed. The decrease in temperature was induced by an increase in the plasma concentration of FQ antimicrobials, suggesting that they are responsible for the temperature reduction. Focusing on glucocorticoids, one thermoregulation mechanism, we investigated the substances responsible for the reduction in rectal body temperature induced by FQ antimicrobials. Aminoglutethimide (an inhibitor of glucocorticoid production) were premedicated, followed by intraperitoneal administration of GFLX in the yeast-induced fever mouse model, resulting in attenuated GFLX-induced hypothermic effects.</p><p><strong>Conclusions: </strong>These results suggest that certain antipyretic effects of CPFX, GFPX, and LVFX during fever may contribute to their hypothermic effects; certain mechanisms are glucocorticoid-mediated.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"10 1","pages":"68"},"PeriodicalIF":1.2,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11533349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142568983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Pharmaceutical Health Care and Sciences
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1